Merus NV
MRUS
View Detailed Chart
95.160USD
-0.020-0.02%
Close 11/06, 16:00（ET）Quotes delayed by 15 min
7.22BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.02%
5 Days
+0.11%
1 Month
+0.94%
6 Months
+141.25%
Year to Date
+126.30%
1 Year
+79.11%
View Detailed Chart
TradingKey Stock Score of Merus NV
Currency: USD Updated: 2025-11-06Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Merus NV's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
17
analysts
Hold
Current Rating
97.533
Target Price
+2.47%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Merus NV Highlights
StrengthsRisks
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
Growing
The company is in a growing phase, with the latest annual income totaling USD 36.13M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 36.13M.
Undervalued
The company’s latest PE is -18.01, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 77.28M shares, decreasing 6.41% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 18.98K shares of this stock.
Merus NV News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Merus NV Info
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
Ticker SymbolMRUS
CompanyMerus NV
CEODr. Sven Ante (Bill) Lundberg, M.D.
Websitehttps://merus.nl/
Related Instruments
+1.26%
+0.52%
+1.05%
+3.23%
+0.85%
+1.65%
-1.33%
-4.02%
+0.67%
+0.98%
+1.00%
+1.70%
-0.18%
+0.34%
+0.88%
+1.07%
0.00%
+0.42%
+1.36%
-0.77%Popular Symbols
